TRI · About · Strategic Plan

Strategic Plan

TRI Story People and Partners TRI Building Reconciliation Action Plan Strategic Plan TRI Foundation Careers

Our next decade

In 2022 TRI celebrated its 10th anniversary. Since the doors opened, we have housed thousands of researchers, engaged with hundreds of clinicians and industry partners, and seen countless breakthroughs in collaborative medical research. This has all led to some remarkable advancements in the treatment of disease.

For the next ten years, our partners have committed to a 2023-2033 Focus, designed to continue the innovation and collaboration that has laid the foundations for our success to date, and serves to outline our approach for the future.

Upholding Research Excellence

Building opportunities for increased knowledge, skills and capacity 

Patient-centred Clinical Trials

Access to better supports and processes for enhanced trial management 

Industry Collaboration

Strong engagement and access to novel technologies and therapies 

Community Connection

Increased visibility and access to data across greater patient cohorts and health consumers

Our first 10 YEARS

Recognising important research contributions

Elizabeth Williams and colleagues Erik Thompson, Euan Wallace, Penny Jeffery and investigators – established the Centre for Personalised Analysis of Cancers network and advanced organoid culture systems, demonstrating utility in improving outcomes in bladder cancer patients.

Peter Soyer and collaborators Monika Janda, Liz Payne, the broader ACEMID team and staff from the Dermatology Research Centre – clinical implementation of VECTRA imaging technology for early detection of melanoma in high-risk patients.

Ingrid Winkler and industry partner GlycoMimetics – Uproleselan development now in Phase 3 clinical trials for the treatment of acute myeloid leukaemia.

Chamindie Punyadeera and collaborators Liz Kenny, Sarju Vasani, Martin Batsone and Yen Kai Lim – a world-first FDA-approved oral saliva throat cancer diagnostic test, CancerDetect

Maher Gandhi and Colm Keane – ground-breaking discoveries in the immunobiology of viral and non-viral-associated lymphomas leading to a new treatment that has been successfully used and is currently being further evaluated in national clinical trials.

Recognition for Microba Life Sciences founding team, including Gene Tyson, Philip Hugenholtz, Nicola Angel and David Wood.

Paul Dawson and colleagues, with the support of Elizabeth Hurrion – demonstrated the importance of sulphate in neonatal brain development, which led to a world-first test now available for routine clinical use.

Ranjeny Thomas and colleagues – developed an immunotherapeutic patent and partnership with Janssen Biotech on a Phase 1 clinical trial of the first antigen-specific tolerising immunotherapy in rheumatoid arthritis.

Vaxxas – developed a high-density microarray patch technology with the potential to transform vaccination by applying vaccines to the skin using a small patch.

Yousuf Mohammed, Jeff Grice, Sarika Namjoshi and Michael Roberts, Xin Liu – recognised for their work with the US FDA improving access to affordable topical medications by revolutionising regulation of generic products.